Pharmacogenetic treatments for drug addiction: Cocaine, amphetamine and methamphetamine

American Journal of Drug and Alcohol Abuse

Volumn 35, Issue 3, 2009, Pages 161-177

  Haile, Colin N ^a   Kosten, Thomas R ^a   Kosten, Therese A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Addiction psychiatry; Drug dependence; Drug therapy; Gene variants; Gene based therapeutics; Genetic variation; Individualized therapy; Pharmacotherapies; Polymorphisms; Stimulants; Subjective effects

Indexed keywords

AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; COCAINE; DISULFIRAM; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE BETA MONOOXYGENASE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; METHYLPHENIDATE; DOPAMINE UPTAKE INHIBITOR; ENZYME INHIBITOR;

3' UNTRANSLATED REGION; ATTENTION DEFICIT DISORDER; COCAINE DEPENDENCE; DRUG DEPENDENCE; DRUG EFFICACY; EUPHORIA; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PARANOIA; PHARMACOGENETICS; PHENOTYPE; PSYCHOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; DRUG ABUSE; GENETICS; METHODOLOGY;

AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; COCAINE-RELATED DISORDERS; DISULFIRAM; DOPAMINE UPTAKE INHIBITORS; ENZYME INHIBITORS; HUMANS; METHAMPHETAMINE; METHYLPHENIDATE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 68249161346     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990902825447     Document Type: Review

References (280)

1. Giacomini, K. M., Brett, C. M., Altman, R. B., Benowitz, N. L., Dolan, M. E., Flockhart, D. A., Johnson, J. A., Hayes, D. F., Kelein, T., Krauss, R. M., Kroetz, D. L.,McLeod, H. L., Nguyen, A. T., Ratain,M. J., Relling, M.V., Reuss,V., Roden, D. M., Schaefer, C. A., Shuldiner, A. R., Skaar, T., Tantisira, K. T., R.F.,Wang, L.,Weinshilboum, R.M.,Weiss, S. T., Zineh, I., and Network, P. R., The pharmacogenetics research network: From SNP discovery to clinical drug response. Clin Pharmacol Ther. 81:(3)328-345 (2007).
2. Liao, G., Zhang, X., Clark, D. J., and Peltz, G., A genomic "roadmap" to "better" drugs. Drug Metab Rev. 40:(2)225-239 (2008).
3. Drolet, B., Simard, C., Mizoue, L., and Roden, D. M., Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest. 115:(8) (2005).
4. Simard,C., Drolet, B.,Yang, P.,R.B., K., andRoden, D. M., Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther. 77:(3)138-144 (2005).
5. Gurbel, P. A., Bliden, K. P., Hiatt, B. L., and O'Connor, C.M., Clopidogrel for coronary stenting: Reponsive variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:(23) (2003).
6. Tantisira, K. G., Hwang, E. S., Raby, B. A., Silverman, E. S., Lake, S. L., Richter, B. G., Peng, S. L.,Drazen, J.M., Glimcher, L. H., andWeiss, S. T., TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA. 101:(52)18099-18104 (2004).
7. Johnson, J. A., Pharmacogenetics: Potential for individualized drug therapy through genetics. Trends Genet. 19:(11)660-666 (2003).
8. Matetzky, S., Shenkman, B., Guetta, V., Shechter, M., Bienart, R., Goldenberg, I., Novikov, I., Savion, N., Varon, D., and Hod, H., Clopidogrel resistance is associated with inicreased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:(25)3171-3175 (2004).
9. Weiss, S. T., Litonju, A. A., Lange,C., Lazarus,R., Liggett, S. B.,Bleecker, E. R., and Tantisira, K. G., Overview of the pharmacogenetics of asthma treatment. Pharmacogenetics J. 6:(5)311-326 (2006).
10. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., and Meyerson, M., EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:(5676)1497-1500 (2004).
11. Holleman, A., Cheok, M. H., Den Boer, M. L., Yang, W., Veerman, A. J., Kazemier, K. M., Pei, D., Cheng, C., Pui, C. H., Relling, M. V., Janka- Schaub, G. E., Pieters, R., and Evans, W. E., Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and reponse to treatment. N Engl J Med 351:(6)601-603 (2004).
12. Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., Desta, Z., Perez, E. A., and Ingle, J. N., Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of eficacy and hot flashes. J Clin Oncol. 23:(36)9312-9318 (2005).
13. Roses, A. D., Pharmacogenetics and drug development: The path to safer and more effective drugs. Nat Rev Genet. 5:(9)645-656 (2004).
14. Shields, A. E. and Lerman, C., Anticipating clinical intetration of pharmacogenetic treatment strategies for addiction: Are primary care physicians ready? Clin Pharmacol Ther. 83:(4)635-639 (2008).
15. Sofuoglu, M. and Kosten, T. R., Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Investig Drugs. 11:(1)91-98 (2006).
16. O'Brien, C. P., Anticraving medications for relapse prevention: A possible new class of psychoactive medications. Am J Psychiatry 162:(8)1423-1431 (2005).
17. Malhotra, A. K., Murphy, G. M. J., and Kennedy, J. L., Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:(5)780-796 (2004).
18. Murphy, G. M. J., Kremer, C., Rodrigues, H. E., and Schatzberg, A. F., Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160:(10)1830-1835 (2003).
19. Gupta, S., Jain, S., Brahmachari, S. K., andKukreti, R., Pharmacogenetics: A path to predictive medicine for schizophrenia. Pharmacogenomics. 7:(1) (2006).
20. deLeon, J.,Armstrong, S. C., and Cozza, K. L., Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 and CYP450 2C19. Psychosomatics. 47:(1)75-85 (2006).
21. Rogers, J. F., Nafziger, A. N., and Bertino, J. S. J., Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 113:(9)746-750 (2002).
22. Scordo, M. G. and Spina, E., Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics. 3:(2)201-218 (2002).
23. Zhang, X. Y., Zhou, D. F., Wu, G. Y., Cao, L. Y., Tan, Y. L., Haile, C. N., Li, J., Lu, L., Kosten, T. A., and Kosten, T. R., BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropharmacology 33:(9)2200-2205 (2008).
24. Zhang, X. Y., Tan, Y. L., Zhou, D. F., Cao, L. Y., Wu, G. Y., Haile, C. N., Kosten, T. A., and Kosten, T. R., Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry. 68:(5)754-760 (2007).
25. Laje, G., Paddock, S., Manji, H., Rush, A. J.,Wilson, A. F., Charney, D. S., andMcMahon, F. J., Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 164:1530-1538 (2007).
26. Leshner, A. I., Addiction is a brain disease, and it matters. Science 278:(5335)45-47 (1997).
27. Weisner, C., Matzger, H., and Kaskutas, L. A., How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals. Addiction 98:(7)901-11 (2003).
28. Simpson, D. D., Joe, G.W., and Broome, K. M., A national 5-year followup of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 59:(6)538-65 (2002).
29. Goldman, D., Oroszi, G., and Ducci, F., The genetics of addictions: Uncovering the genes. Nat Rev Genet. 6:(7)521-532 (2005).
30. Yacubian, J., Sommer, T., Schroeder, K., Glascher, J., Braus, D. F., and Buchel, C., Subregions of the ventral striatum show preferential coding of reward magnitude and probability. Neuroimage. 38:(3)557-563 (2007).
31. Haile, C. N., Hiroi, N., Nestler, E. J., and Kosten, T. A., Differential behavioral responses to cocaine are associated with dynamics of mesolimbic dopamine proteins in Lewis and Fischer 344 rats. Synapse 41:179-190 (2001).
32. Haile, C. N., Kosten, T. R., and Kosten, T. A., Genetics of dopamine and its contribution to cocaine addiction. Behav Genet. 37:(1)119-145 (2007).
33. Haile, C. N. and Kosten, T. A., Differential effects of D1- and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats. J Pharmacol Exp Ther. 299:(2)509-518 (2001).
34. Gabbay, F. H., Variations in affect following amphetamine and placebo: markers of stimulant drug preference. Exp Clin Psychopharmacol. 11:(1)91-101 (2003).
35. Lott, D. C.,Kim, S. J., Cook, E. H. J., and De Wit, H., Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 30:(3)602-609 (2005).
36. Haile, C. N.,Kosten, T. A., andKosten, T. R., Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates. Am J Drug Alcohol Abuse 34:355-381 (2008).
37. Nestler, E. J., Is there a common molecular pathway for addiction? Nat Neurosci. 8:(11)1445-1449 (2005).
38. Heffner, T. G., Hartman, J. A., and Seiden, L. S., Feeding increases dopamine metabolism in the rat brain. Science 208:1168-1170 (1980).
39. Volkow, N. D. andWise, R. A., How can drug addiction help us understand obesity? Nat Neurosci. 8:(5)555-560 (2005).
40. Robinson, T. E. and Berridge, K. C., Addiction. Annu Rev Psychol. 54:75-114 (2003).
41. Hyman, S. E. and Malenka, R. C., Addiction and the brain: The neurobiology of compulsion and its persistence. Nat Rev Neurosci. 2:(10)695-703 (2001).
42. Everitt, B. J., Cardinal, R. N., Parkinson, J. A., and Robbins, T.W., Appetitive behavior: Impact of amygdala-dependent mechanisms of emotional learning. Ann NY Acad Sci. 985:233-250 (2003).
43. Kalivas, P. W., Glutamate systems in cocaine addiction. Curr Opin Pharmacol. 4:(1)23-29 (2004).
44. Roberts, D. C. and Koob, G. F., Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental. Pharmacol Biochem Behav. 17:901-904 (1982).
45. DiChiara, G. and Imperato, A., Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 85:5274-5278 (1988).
46. Pettit, H. O., Ettenberg, A., Bloom, F. E., and Koob, G. F., Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology 84:167-173 (1984).
47. Zito, K. A., Vickers, G., and Roberts, D. C., Disruption of cocaine and heroin self-administration following kainic acid lesions of the nucleus accumbens. Pharmacol Biochem Behav. 23:1029-1036 (1985).
48. Glowinski, J. and Iversen, L. L., Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 13:655-669 (1966).
49. Snyder, S. H. and Coyle, J. T., Regional differences in H3-norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther. 165:78-86 (1969).
50. Lewis, D. A., Melchitzky, D. S., Sesack, S. R., Whitehead, R. E., Auh, S., and Sampson, A., Dopamine transporter immunoreactivity in monkey cerebral cortex: Regional, laminar, and ultrastructural localization. J Comp Neurol. 432:(1)119-136 (2001).
51. Mazei, M. S., Pluto, C. P., Kirkbride, B., and Pehek, E. A., Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res. 936:(1-2)58-67 (2002).
52. Moron, J. A., Brockington, A.,Wise, R. A., Rocha, B. A., and Hope, B. T., Dopamine uptake through the norepinephrine transporter in brain regions with low levels of dopamine transporter: Evidence from knock-out mouse lines. J Neurosci. 22:(2)389-395 (2002).
53. Nestler, E. J., Molecular neurobiology of addiction. Am J Addict. 10:201-217 (2001).
54. Greengard, P., Allen, P. B., and Nairn, A. C., Beyond the dopamine receptor: The DARPP-32/protein phosphatase-1 cascade. Neuron 23:435-447 (1999).
55. Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M., and Nestler, E. J., A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res. 548:100-110 (1991).
56. Pierce, R. C. and Kalivas, P. W., A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev. 25:192-216 (1997).
57. Schank, J. R., Liles, L. C., andWeinshenker, D., Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaineinduced anxiety. Biol Psychiatry 63:(11)1007-1012 (2008).
58. Robinson, T. E. and Berridge, K. C., The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Rev. 18:247-291 (1993).
59. Bartlett, E., Hallin, A., Chapman, B., and Angrist, B., Selective sensitization to the psychosis-inducing effects of cocaine: A possible marker for addiction relapse vulnerability? Neuropsychopharmacology. 16:(1)77-82 (1997).
60. Gawin, F. H. and Kleber, H. D., Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 43:(2)107-113 (1986).
61. Hart, C. L., Ward, A. S., Haney, M., Foltin, R. W., and Fischman, M. W., Methamphetamine self-administration by humans. Psychopharmacology 157:75-81 (2001).
62. Fischman, M. W. and Schuster, C. R., Cocaine self-administration in humans. Fed Proc. 41:241-246 (1982).
63. Wachtel, S. R. and De Wit, H., Subjective and behavioral effects of repeated d-amphetamine in humans. Behav Pharm. 10:(3)271-281 (1999).
64. Vollm, B. A., De Araujo, I. E., Cowen, P. J., Rolls, E. T., Kringelbach, M. L., Smith, K. A., Jessard, P., Heal, R. J., and Matthews, P. M.,Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology. 29:1715-1722 (2004).
65. Volkow, N. D.,Wang, G. J., Fowler, J. S., Logan, J., Gatley, S. J., Gifford, A., Hitzemann, R., Ding, Y. S., and Pappas, N., Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 156:(9)1440-1443 (1999).
66. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Gatley, S. J., Hitzemann, R., Chen, A. D., Dewey, S. L., and Pappas, N., Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:(6627)830-833 (1997).
67. Laruelle, M., Gelernter, J., and Innis, R. B., D2 receptors binding potential is not affected by Taq1 polymorphisms at the D2 receptor gene. Mol Psychiatry. 3:(3)261-265 (1998).
68. Romach, M. K., Glue, P., Kampman, K., Kaplan, H. L., Somer, G. R., Poole, S., Clarke, L., Coffin, V., Cornish, J., O'Brien, C. P., and Sellers, E. M., Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry. 56:(12)1101-1106 (1999).
69. Sherer, M. A., Kumor, K. M., and Jaffe, J. H., Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 27:(2)117-25 (1989).
70. Newton, T. F., Ling, W., Kalechstein, A. D., Uslaner, J., and Tervo, K., Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res. 102:(3)227-33 (2001).
71. Alhassoon, O. M., Dupont, R. M., Schweinsburg, B. C., Taylor, M. J., Patterson, T. L., and Grant, I., Regional cerebral blood flow in cocaineversus methamphetamine-dependent patients with a history of alcoholism. Int J Neuropsychopharmacol. 4:105-112 (2001).
72. Hall, F. S., Sora, I., Drgonova, J., Li, X. F., Goeb, M., and Uhl, G. R., Molecular mechanisms underlying the rewarding effects of cocaine. Ann N Y Acad Sci. 1025:47-56 (2004).
73. Shoptaw, S., Watson, D. W., Reiber, C., Rawson, R. A., Montgomery, M. A., Majewska, M. D., and Ling, W., Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 11:(1)78-90 (2005).
74. Kosten, T. R., George, T. P., and Kosten, T. A., The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs. 11:(4)491-499 (2002).
75. Kosten, T. R., Morgan, C., and Kosten, T. A., Treatment of heroin addicts using buprenorphine.H. Am J Drug Alcohol Abuse 17:(2)119-128 (1991).
76. Shoptaw, S.,Yang, X., Rotheram-Fuller, E. J., Hsieh,Y. C., Kintaudi, P. C., Charuvastra, V. C., and Ling, W., Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 64:(12)1440-1448 (2003).
77. Gonzalez, G., Servarino, K., Sofuoglu, M., Poling, J., Oliveto, A., Gonsai, K., George,T. P., andKosten,T.R.,Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: Results of a randomized pilot study. Addiction 98:(11)1625-1632 (2003).
78. Hameedi, F. A., Rosen, M. I., McCance-Katz, E. F., McMahon, T. J., Price, L. H., Jatlow, P. I., Woods, S. W., and Kosten, T. R., Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry. 37:(8)560-563 (1995).
79. Carroll, K. M., Fenton, L. R.,Ball, S. A., Nich,C., Frankforter, T. L., Shi, J., and Rounsaville, B. J., Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Arch Gen Psychiatry 61:264-272 (2004).
80. Cubells, J. F. and Zabetian, C. P., Human genetics of plasma dopamine beta-hydroxylase activity: Applications to research in psychiatry and neurology. Psychopharmacology 174:(4)463-476 (2004).
81. Mikami, L. R., Wieseler, S., Souza, R. L., Schopfter, L. M., Nachon, F., Lockridge, O., and Chautard-Freire-Maia, E. A., Five new naturally occurring mutations of the BCHE gene and frequencies of 12 butyrylcholinesterase alleles in aBrazilian population. PharmacogenetGenomics. 18:(3)213-218 (2008).
82. Towell, J. F. r., Cho, J. K., Roh, B. L., and Wang, R. I., Disulfiram and erythrocyte aldehyde dehydrogenase inhibition. Clin Pharmacol Ther. 33:(4)517-521 (1983).
83. Johnson, S. M. and Fleming,W.W.,Mechanisms of cellular adaptive sensitivity changes: Applications to opioid tolerance and dependence. Pharmacol Rev. 41:(4)435-488 (1989).
84. Vaccari, A., Saba, P. L., Ruiu, S., Collu, M., and Devoto, P., Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine. Toxicol Appl Pharmacol. 139:(1)102-108 (1996).
85. Bourdelat-Parks, B. N., Anderson, G. M., Donaldson, Z. R., Weiss, J. M., Bonsall, R. W., Emery, M. S., Liles, L. C., and Weinshenker, D., Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology 183:(1)72-80 (2005).
86. Schank, J. R., Ventura, R., Puglisi-Allegra, S., Alcaro, A., Cole, C. D., Liles, L.C., Seeman, P., andWeinshenker, D., Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology. 31:(10)2221-2230 (2006).
87. McCance-Katz, E. F., Kosten, T. R., and Jatlow, P., Chronic disulfiram treatment effects on intranasal cocaine administration: Initial results. Biol Psychiatry 43:(7)540-543 (1998).
88. McCance-Katz, E. F., Kosten, T. R., and Jatlow, P., Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 52:(1)27-39 (1998).
89. Wright, C. and Moore, R. D., Disulfiram treatment of alcoholism. Am J Med. 88:(6)647-655 (1990).
90. Suh, J. J., Pettinati, H. M., Kampman, K. M., and O'Brien, C. P., The status of disulfiram: A half of a century later. J Clin Psychopharmacol. 26:(3)290-302 (2006).
91. Carroll, K. M., Nich, C., Ball, S. A., McCance, E., and Rounsavile, B. J., Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93:(5)713-727 (1998).
92. Carroll, K. M., Power, M. E., Bryant, K., and Rounsaville, B. J., Oneyear follow-up status of treatment-seeking cocaine abusers. Psychopathology and dependence severity as predictors of outcome. J Nerv Ment Dis. 181:(2)71-79 (1993).
93. George, T. P., Chawarski, M. C., Pakes, J., Carroll, K. M., Kosten, T. R., and Schottenfeld,R. S., Disulfiram versus placebo for cocaine dependence in buprenorphine maintained subjects: A preliminary trial. Biol Psychiatry 47:(12)1080-1086 (2000).
94. Higgins, S. T., Budney, A. J., Bickel, W. K., Hughes, J. R., and Foerg, F., Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 150:(4)675-676 (1993).
95. Petrakis, I. L., Carroll, K. M., Nich, C., Gordon, L. T., McCance-Katz, E. F., Frankforter, T. L., and Rounsaville, B. J., Disulfiram treatment for cocaine dependence in methadone maintained opioid addicts. Addiction 95:(2)219-228 (2000).
96. McCance-Katz, E. F., Price, L. H., McDougle, C. J., Kosten, T. R., Black, J. E., and Jatlow, P. I., Concurrent cocaine ethanol ingestion in humans: Pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology 111:(1)39-46 (1993).
97. Carroll, K. M., Nich, C., Ball, S. A., McCance, E., Frankforter, T. L., and Rounsaville, B. J., One year followup of disulfiram and psychotherapy for cocaine alcohol users: Sustained effects of treatment. Addiction 95:(9)1335-1349 (2000).
98. Martensen-Larsen, O., Psychotic phenomena provoked by tetraethylthiuram disulfide. Q J Stud Alcohol. 12:(2)206-216 (1951).
99. Kalayasiri, R., Sughondhabirom, A., Gueorguie va, R., Coric V, L., W.J., Morgan, P. T., Cubells, J. F., andMalison, R. T., Selfreported paranoia during laboratory "binge" cocaine selfadministration in humans. Pharmacol Biochem Behav. 83:(2)249-256 (2006).
100. Baker, J. R., Jatlow, P., and McCance-Katz, E. F., Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 87:(2-3)202-209 (2007).
101. Haile, C. N., During, M. J., Jatlow, P. I., Kosten, T. R., and Kosten, T. A., Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. Biol Psychiatry 54:915-921 (2003).
102. Cubells, J. F., Kranzler, H. R., McCance-Katz, E. F., Anderson, G. M., Malison, R. T., Price, L. H., and Gelernter, J., A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol Psychiatry. 5:(1)56-63 (2000).
103. Stewart, L. C. and Klinman, J. P., Dopamine beta-hydroxylase of adrenal chromaffin granules: Structure and function. Annu Rev Biochem. 57:551-592 (1988).
104. Kaufman, S. and Friedman, S., Dopamine-beta-hydroxylase. Pharmacol Rev. 17:71-100 (1965).
105. Senard, J.-M. and Rouet, P., Dopamine beta-hydroxylase deficiency. Orphanet J Rare Dis 1:(7)1-4 (2006).
106. Deinum, J., Steenbergen-Spanjers, G. C., Jansen, M., Boomsma, F., Lenders, J. W., Van Ittersum, F. J., Hück, N., Van Den Heuvel, L. P., and Wevers, R. A., DBH gene variants that cause low plasma dopamine beta hydroxylase with or without a severe orthostatic syndrome. A. J Med Genet. 41:(4)e38 (2004).
107. Garland, E. M., Black, B. K., Harris, P. A., and D., R., Dopamine-betahydroxylase in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 293:H684-H690 (2007).
108. Grzanna, R. and Coyle, J. T., Immunochemical studies on the turnover of rat serum dopamine beta-hydroxylase. Mol Pharmacol. 13:(5)956-964 (1977).
109. Weinshilboum,R.M., Serum dopamine beta-hydroxylase. Pharmacol Rev. 30:(2)133-166 (1978).
110. Paclt, I. and Koudelov́a, J., Changes of dopamine-beta-hydroxylase activity during ontogenesis in healthy subjects and in an experimental model (rats). Physiol Res. 53:(6)661-667 (2004).
111. Ross, S. B., Wetterberg, L., and Myrhed, M., Genetic control of plasma dopamine-beta-hydroxylase. Life Sci. 12:(12)529-532 (1973).
112. Weinshilboum, R. M., Raymond, F. A., Elveback, L. R., and Weidman, W. H., Serum dopamine-beta-hydroxylase activity: Sibling-sibling correlation. Science 181:(103)943-945 (1973).
113. Oxenstierna, G., Edman, G., Iselius, L., Oreland, L., Ross, S. B., and Sedvall, G., Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals-a genetic study. J Psychiatr Res. 20:(1)19-29 (1986).
114. Wei, J., Ramchand, C. N., and Hemmings, G. P., Possible control of dopamine beta-hydroxylase via a codominant mechanism associated with the polymorphic (GT)n repeat at its gene locus in healthy individuals. Hum Genet. 99:(1)52-55 (1997).
115. Cubells, J. F., vanKammen, D. P., Kelley, M. E., Anderson, G. M., O'Connor, D. T., Price, L. H., Malison, R. T., Rao, P. A., Kobayashi, K., Nagatsu, T., and Gelernter, J., Dopamine beta-hydroxylase: Two polymorphisms in linkage disequilibrium at the structural geneDBH associate with biochemical phenotypic variation. Hum Genet. 102:(5)533-540 (1998).
116. Zabetian, C. P., Anderson, G. M., Buxbaum, S. G., Elston, R. C., Ichinose, H., Nagatsu, T., Kim, K. S., Kim, C. H., Malison, R. T., Gelernter, J., and Cubells, J. F., A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus. Am J Genet. 68:(2)515-522 (2001).
117. Zabetian, C. P., Buxbaum, S. G., Elston, R. C., Kohnke, M. D., Anderson, G. M., Gelernter, J., and Cubells, J. F., The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. Am J Genet. 72:(6)1389-1400 (2003).
118. Kohnke, M. D., Zabetian, C. P., Anderson, G. M., Kolb, W., Gaertner, I., Buchkremer, G., Vonthein, R., Schick, S., Lutz, U., Kohnke, A. M., and Cubells, J. F., A genotype-controlled analysis of plasma dopamine betahydroxylase in healthy and alcoholic subjects: Evidence for alcohol-related differences in noradrenergic function. Biol Psychiatry 52:(12)1151-1158 (2002).
119. Bhaduri, N. and Mukhopadhyay, K., Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: A study on eastern Indian populaion. Cell Mol Neurobiol 28:343-350 (2008).
120. Cadet, J.-L., Jayanthi, S., and Deng, X., Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J. 17:1775-1788 (2003).
121. Tang, Y. L., Epstein,M. P., Anderson, G. M., Zabetian, C. P., and Cubells, J. F., Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans. Eur J Hum Genet. 15:(8)878-883 (2007).
122. Guindalini, C., Laranjeira, R., Collier, D., Messas, G., Vallada, H., and Breen, C., Dopamine-beta hydroxylase polymorphism and cocaine addiction. Behav Brain Funct 3:(4)1-4 (2008).
123. Tsuang, M. T., Lyons, M. J., Meyer, J. M., Doyle, T., Eisen, S. A., Goldberg, J., True, W., Lin, N., Toomey, R., and Eaves, L., Co-occurrence of abuse of different drugs in men: The role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry. 55:(11)967-972 (1998).
124. Wei, J., Ramchand, C. N., and Hemmings, G. P., TaqI polymorphic sites at the human dopamine beta-hydroxylase gene possibly associated with biochemical alterations of the catecholamine pathway in schizophrenia. Psychiatr Genet. 8:(1)19-24 (1998).
125. Cubells, J. F., Price, L. H., Meyers, B. S., Anderson, G. M., Zabetian, C. P., Alexopoulos, G. S., Nelson, J. C., Sanacora, G., Kirwin, P., Carpenter, L., Malison R.T., and Gelernter, J., Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biol Psychiatry 51:(5)358-364 (2002).
126. Freire, M. T., Hutz, M. H., and Bau, C. H., The DBH -1021 C/T polymorphism is not associated with alcoholism but possibly with patients' exposure to life events. J Neural Transm. 112:(9)1269-1274 (2005).
127. Tang, Y., Buxbaum, S. G.,Waldman, I., Anderson, G. M., Zabetian, C. P., Köhnke, M. D., and Cubells, J. F., A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms. Biol Psychiatry 60:(10)1034-1038 (2006).
128. Mustapic, M., Pivac, N., Kozaric-Kovacic, D., Dezeljin,M., Cubells, J. F., and Muck-Seler, D., Dopamine beta-hydroxylase (DBH) activity and - 1021C/T polymorphism of DBH gene in combat-related post-traumatic stress disorder. Am J Med Genet B Neuropsychiatr Genet. 144:(8)1087-1089 (2007).
129. Rogeness, G. A., Maas, J. W., Javors, M. A., Macedo, C. A., Harris, W. R., and Hoppe, S. K., Diagnoses, catecholamine metabolism, and plasma dopamine-beta-hydroxylase. J Am Acad Child Adolesc Psychiatry. 27:(1)121-125 (1988).
130. Rogeness, G. A., Javors, M. A., Maas, J. W., Macedo, C. A., and Fischer, C., Plasma dopamine-beta-hydroxylase, HVA, MHPG, and conduct disorder in emotionally disturbed boys. Biol Psychiatry. 22:(9)1158-1162 (1987).
131. Rogeness, G. A., Hernandez, J. M., Macedo, C. A., Mitchell, E. L., Amrung, S. A., and Harris, W. R., Clinical characteristics of emotionally disturbed boys with very low activities of dopamine-beta-hydroxylase. J Am Acad Child Psychiatry. 23:(2)203-208 (1984).
132. Rogeness, G. A., Hernandez, J. M., Macedo, C. A., Amrung, S. A., and Hoppe, S. K., Near-zero plasma dopamine-beta-hydroxylase and conduct disorder in emotionally disturbed boys. J Am Acad Child Psychiatry. 25:(4)521-527 (1986).
133. Galvin, M., Shekhar, A., Simon, J., Stilwell, B., Ten Eyck, R., Laite, G., Karwisch, G., and Blix, S., Low dopamine-beta-hydroxylase: A biological sequela of abuse and neglect? Psychiatry Res. 39:(1)1-11 (1991).
134. Healy, D. G., Abou-Sleiman, P. M., Ozawa, T., Lees, A. J., Bhatia, K., Ahmadi, K. R., Wullner, U., Berciano, J., Moller, J. C., Kamm, C., Burk, K., Barone, P., Tolosa, E., Quinn, N., Goldstein, D. B., and Wood, N. W., A functional polymorphism regulating dopamine beta-hydroxylase influences against Parkinson's disease. Ann Neurol. 55:(3)443-446 (2004).
135. Jonsson, E. G., Bah, J., Melke, J., Abou Jamra, R., Schumacher, J., Westberg, L., Ivo, R., Cichon, S., Propping, P., Nathen, M. M., Eriksson, E., and Sedvall, G. C., Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. BMC Psychiatry. 4:(4) (2004).
136. Kalayasiri, R., Sughondhabirom, A., Gueorguieva, R., Coric, V., Lynch, W. J., Lappalainen, J., Gelernter, J., Cubells, J. F., and Malison, R. T., Dopamine beta-hydroxylase gene (DbetaH) -1021C-T influences selfreported paranoia during cocaine self-administration. Biol Psychiatry. 61:(11)1310-1313 (2007).
137. Sughondhabirom, A., Jain, D., Gueorguieva, R., Corvic, V., Berman, R., Lynch,W. J., Self,D.W., Jatlow, P., and R.T.,M.,Aparadigm to investigate the self-regulation of cocaine administration in humans. Psychopharmacology 180:(3)436-446 (2005). (Pubitemid 40905033)
138. Brady, K. T., Lydiard, R. B., Malcolm, R., and Ballenger, J. C., Cocaineinduced psychosis. J Clin Psychiatry. 52:(12)509-512 (1991).
139. Satel, S. L. and Edell, W. S., Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 148:(12)1708-1711 (1991).
140. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Hitzemann, R., Ding, Y. S., Pappas, N., Shea, C., and Piscani, K., Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res. 20:1594-1598 (1996).
141. Volkow, N. D., Fowler, J. S.,Wolf, A. P., Schlyer, D., Shiue, C. Y., Alpert, R., Dewey, S. L., Logan, J., Bendriem, B., and Christman, D. e. a., Effectsof chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147:(6)719-724 (1990).
142. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M. J., Gately, S. J., Hitzemann, R., Ding, Y. S., Wong, C., and Logan, J., Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry. 158:383-389 (2001).
143. Wang, G. J.,Volkow, N. D., Fowler, J. S., Logan, J.,Abumrad, N. N., Hitzemann, R. J., Pappas, N. S., and Pascani, K., Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropharmacology 16:(2)174-182 (1997).
144. Volkow, N. D., Wang, G. J., Fowler, J. S., Thanos, P., Logan, J., Gatley, S. J., Gifford, A., Ding, Y. S., Wong, C., and Pappas, N., Brain DA D2 receptors predict reinforcing effects of stimulants in humans: Replications study. Synapse 46:(2)79-82 (2002).
145. Zubieta, J. K., Gorelick, D. A., Stauffer, R., Ravert, H. T., Dannals, R. F., and Frost, J. J., Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med. 2:(11)1225-1229 (1996).
146. Heinz, A., Siessmeier, T., Wrase, J., Hermann, D., Klein, S., Grüsser, S. M., Flor, H., Braus, D. F., Buchholz, H. G., Gründer, G., Schreckenberger,M., Smolka, M. N., Rösch, F., Mann, K., and Bartenstein, P., Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 161:(10)1741-1742 (2004).
147. Volkow, N. D., Wang, G. J., Begleiter, H., Porjesz, B., Fowler, J. S., Telang, F.,Wong, C., Ma, Y., Logan, J., Goldstein, R. Z., Alexoff, D., and Thanos, P., High levels of dopamine D2 receptors in unaffected members of alcoholic families: Possible protective factors. Arch Gen Psychiatry. 63:(9)999-1008 (2006).
148. Dalley, J. W., Fryer, T. D., Brichard, L., Robinson, E. S., Theobald, D. E., Lääne, K., Peña, Y., Murphy, E. R., Shah, Y., Probst, K., Abakumova, I., Aigbirhio, F. I., Richards, H. K., Hong, Y., Baron, J. C., Everitt, B. J., and Robbins, T. W., Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science. 315:(5816)1267-1270 (2007).
149. Flores, G., Wood, G. K., Barbeau, D., Queirion, R., and Srivastava, l. K., Lewis and Fischer rats: A comparison of dopamine transporter and receptor levels. Brain Res. 814:(1-2)34-40 (1998).
150. Stefanini, E., Frau, M., Garau, M. G., Garau, B., Fadda, F., and Gessa, G. L., Alcohol-preferring rats have fewer dopamine D2 receptors in the limbic system. Alcohol Alcohol. 27:(2)127-130 (1992).
151. McBride, W. J., Chernet, E., Dyr, W., Lumeng, L., and Li, T. K., Densities of dopamine D2 receptors are reduced in CNS regions of alcoholpreferring P rats. Alcohol. 10:(5)387-390 (1993).
152. Maldonado, R., Saiardi, A., Valverde, O., Samad, T. A., Roques, B. P., and Borrelli, E.,Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature. 388:(6642)586-589 (1997). (Pubitemid 27340008)
153. Phillips, T. J., Brown, K. J., Burkhart-Kasch, S., Wenger, C. D., Kelly, M. A., Rubinstein, M., Grandy, D. K., and Low, M. J., Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors. Nat Neurosci. 1:(2)610-615 (1998).
154. Wang, G. J., Volkow, N. D., Chang, L., Miller, E., Sedler, M., Hitzemann, R., Zhu, W., Logan, J., Ma, Y., and Fowler, J. S., Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry. 31:313-319 (2004).
155. Kawarai, T., Kawakami, H., Yamamura, Y., and Nakamura, S., Structure and organization of the gene encoding human dopamine transporter. Gene 195:(1)11-18 (1997).
156. Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Ding, Y. S., Logan, J., Dewey, S. L., Hitzemann, R., and Lieberman, J., Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. Proc Natl Acad Sci U S A. 93:(19)10388-10392 (1996).
157. Ritz, M. C., Lamb, R. J., Goldberg, S. R., and Kuhar, M. J., Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223 (1987).
158. Sulzer, D., Sonders, M. S., Poulsen, N. W., and Galli, A., Mechanisms of neurotransmitter release by amphetamines: A review. Prog in Neurobiol. 75:406-433 (2005).
159. Liang, N. Y. and Rutledge, C. O., Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol. 31:983-992 (1982).
160. Haile, C. N., Neurochemical and Neurobehavioral consequences of methamphetamine abuse., in Drug Abuse Handbook, Second Ed. (S. B. Karch, Ed.), CRC Press, Boca Raton, FL, 33487, 2007, pp. 478-503.
161. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., and Caron, M. G., Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:(6566)606-612 (1996).
162. Mitchell, R. J.,Howlett, S., Earl, L., White, N. G., McComb, J., Schanfield, M. S., Briceno, I., Papiha, S. S., Osipova, L., Livshits, G., Leonard,W. R., and Crawford, M. H., Distribution of the 3- VNTR polymorphism in the human dopamine transporter gene in world populations. Hum Biol. 72:(2)295-304 (2000).
163. Doucette-Stamm LA, B. D., Tian J, Mockus S, Mao JI., Population genetic study of the human dopamine transporter gene (DAT1). Genet Epidemiol. 12:(3)303-308 (1995).
164. Kang, A. M., Palmatier, M. A., and Kidd, K. K., Global variation of a 40-bp VNTR in the 3--untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 46:(2)151-160 (1999).
165. Fuke, S., Suo, S., Takahashi, N., Koike, H., Sasagawa, N., and Ishiura, S., The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 1:(2)152-156 (2001).
166. Mill, J., Asherson, P., Browes, C., D'Souza, U., and Craig, I., Expression of the dopamine transporter gene is regulated by the 3- UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet. 114:(8)975-979 (2002).
167. VanNess, S. H., Owens, M. J., and Kilts, C. D., The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 27:(6)55 (2005).
168. Biederman, J., Petty, C. R., Wilens, T. E., Fraire, M. G., Purcell, C. A., Mick, E., Monuteaux, M. C., and Faraone, S. V., Familial risk analyses of attention deficit hyperactivity disorder adn substance use disorders. Am J Psychiatry 165:(1)107-115 (2008).
169. Barkley, R. A., Psychosocial treatments for attention-deficit/ hyperactivity disorder in children. J Clin Psychiatry. 63:(12)36-43 (2002).
170. Aylward, E. H., Reiss, A. L., Reader,M. J., Singer, H. S., Brown, J. E., and Denckla, M. B., Basal ganglia volumes in children with attention-deficit hyperactivity disorder. J Child Neurol. 11:(2)112-115 (1996).
171. Castellanos, F. X., Giedd, J. N., Marsh,W. L., Hamburger, S. D., Vaituzis, A. C., Dickstein, D. P., Sarfatti, S. E., Vauss, Y. C., Snell, J.W., Lange, N., Kaysen, D., Krain, A. L., Ritchie, G. F., Rajapakse, J. C., and Rapoport, J. L., Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 53:(7)607-616 (1996). (Pubitemid 26240863)
172. Ernst, M., Zametkin, A. J., Matochik, J. A., Jons, P. H., and Cohen, R. M., DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci. 18:(15)5901-5907 (1998).
173. Krause, K. H., Dresel, S. H., Krause, J., Kung, H. F. E. A., and Tatsch, K., Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission tomography. Neurosci Lett. 285:(2)107-110 (2000).
174. Krause, K. H., Dresel, S. H., Krause, J., Kung, H. F. E. A., Tatsc, K., and Lochmuller, H., Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome adn attention deficit/hyperactivity disorder: Positive effect of methylphenidate. J Neurol. 249:(8)1116-1118 (2002).
175. Zametkin, A. J., Liebenauer, L. L., Fitzgerald, G. A., King, A. C., Minkunas, D. V., Herscovitch, P., Yamada, E. M., and Cohen, R. M., Brain metabolism in teenagers with attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 50:(5)333-40 (1993).
176. Wilens, T. E. and Upadhyaya, H. P., Impact of substance use disorder on ADHD and its treatment. J Clin Psychiatry. 68:(8)e20 (2007).
177. Volkow, N. D., Fowler, J. S., Wang, G. J., Swanson, J. M., and Telang, F., Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Arch Neurol. 64:(11)1575-1579 (2007).
178. Cook, E. H. J., Stein, M. A., Krasowski, M. D., Cox, N. J., Olkon, D. M., Kieffer, J. E., and Leventhal, B. L.,Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet. 56:(4)993-998 (1995).
179. Waldman, I. D., Rowe, D. C., Abramowitz, A., Kozel, S. T., Mohr, J. H., Sherman, S. L., Cleveland, H. H., Sanders, M. L., Gard, J. M., and Stever, C., Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: Heterogeneity owing to diagnositc subtype and severity. Am J Hum Genet. 63:(6)1767-1776 (1998).
180. Daly, G., Hawi, Z., Fitzgerald, M., and Gill, M., Mapping susceptibility loci in attention deficit hyperactivity disorder: Preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry. 4:(2)192-196 (1999).
181. Brookes,K. J., Mill, J.,Guindalini, C., Curran, S., Xu, X., Knight, J., Chen, C. K., Huang, Y. S., Sethna, V., Taylor, E., Chen,W., Breen, G., and Asherson, P., A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry. 63:(1)74-81 (2006).
182. Muglia, P., Jain, U., Inkster, B., and Kennedy, J. L., A quantitative trait locus analysis of the dopamine transporter gene in adults with ADHD. Neuropsychopharmacology. 27:(4)655-662 (2002).
183. Kim, D. J., Roh, S., Kim, Y. J., Yoon, S. J., Lee, H. K., Han, C. S., and Kim, Y. K., High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci Lett. 388:(2)112-115 (2005).
184. Bellgrove, M. A., Chambers, C. D., Johnson, K. A., Daibhis, A., Daly, M., Hawi, Z., Lambert, D., Gill, M., and Robertson, I. H., Dopaminergic genotype biases spatial attention in healthy children. Mol Psychiatry. 12:(8)786-792 (2007).
185. Guindalini, C., Howard, M., Haddley, K., Laranjeira, R., Collier, D., Ammar, N., Craig, I., O'Gara, C., Bubb, V. J., Greenwood, T., Kelsoe, J., Asherson, P., Murray, R. M., Castelo, A., Quinn, J. P., Vallada, H., and Breen, G., A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A. 103:(12)4552-4557 (2006).
186. Winsberg, B. G. and Comings, D. E., Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry. 38:(12)1474-1477 (1999).
187. Roman, T.,Rohde, L. A., andHutz, M. H., Polymorphisms of the dopamine transporter gene: Influence on response to methylphenidate in attention deficit-hyperactivity disorder. Am J Pharmacogenomics. 4:(2)83-92 (2004).
188. Cheon, K. A., Ryu,Y. H., Kim, J.W., and Cho, D.Y., The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: Relating to treatment response to methylphenidate. Eur Neuropsychopharmacol. 15:(1)95-101 (2005).
189. Kooij, J. S., Boonstra, A. M., Vermeulen, S. H., Heister, A. G., Burger, H., Buitelaar, J. K., and Franke, B., Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am J Med Genet B Neuropsychiatr Genet. oct 22 epub: (2007).
190. Gilbert, D. L., Wang, Z., Sallee, F. R., Ridel, K. R., Merhar, S., Zhang, J., Lipps, T. D., White, C., Badreldin, N., andWassermann, E. M., Dopamine transporter genotype influences the physiological response to medication in ADHD. Brain 129:(8)2038-2046 (2006).
191. Joober, R.,Grizenko, N., Sengupta, S., Amor, L.B., Schmitz, N., Schwartz, G., Karama, S., Lageix, P., Fathalli, F., Torkaman-Zehi, A., and Ter Stepanian, M., Dopamine transporter 3--UTR VNTR genotype and ADHD: A pharmaco-behavioural genetic study with methylphenidate. Neuropsychopharmacology. 32:(6)1370-1376 (2007).
192. Mick, E., Biederman, J., Spencer, T., Faraone, S. V., and Sklar, P., Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet B Neuropsychiatr Genet. 141:(8)890-894 (2006).
193. Krause, J., Dresel, S. H., Krause, K. H., La Foug̀ere, C., Zill, P., and Ackenheil, M., Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: No higher DAT availability in patients with homozygosity for the 10-repeat allele. World J Biol Psychiatry. 7:(3)152-157 (2006).
194. Kirley, A., Lowe, N., Hawi, Z., Mullins, C., Daly, G., Waldman, I., Mc- Carron, M., O'Donnell, D., Fitzgerald, M., and Gill, M., Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet. 121:(1)50-54 (2003).
195. Stein, M. A., Waldman, I. D., Sarampote, C. S., Seymour, K. E., Robb, A. S., Conlon, C., Kim, S. J., and Cook, E. H., Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 30:(7)1374-1382 (2005).
196. Levin, F. R., Evans, S. M., Brooks, D. J., and Garawi, F., Treatment of cocaine dependent treatment seekerswith adultADHD:double-blind comparison ofmethylphenidate and placebo. Drug Alcohol Depend. 87:(1)20-29 (2007).
197. Collins, S. L., Levin, F. R., Foltin, R.W., Kleber, H. D., and Evans, S. M., Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend. 82:(2)158-167 (2006).
198. Volkow, N. D., Hitzemann, R., Wang, G. J., Fowler, J. S., Wolf, A. P., Dewey, S. L., and Handlesman, L., Long-term frontal brain metabolic changes in cocaine abusers. Synapse 11:(3)184-190 (1992).
199. Rosenkranz, J. A. and Grace, A. A., Dopamine attenuates prefrontal cortical suppression of sensory inputs to the basolateral amygdala of rats. J Neurosci. 21:(11)4090-4103 (2001).
200. Goldstein, R. Z., Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Depue, R. A., and Gur, R. C., Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 59:(10)1642-1652 (2002).
201. Heinz, A., Goldman, D., Jones, D.W., Palmour, R., Hommer, D., Gorey, J. G., Lee, K. S., Linnoila, M., and Weinberger, D. R., Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22:(2)133-139 (2000).
202. Martinez, D., Gelernter, J., Abi-Dargham, A., Van Dyck, C. H., Kegeles, L., Innis, R. B., and Laruelle, M., The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24:(5)553-560 (2001).
203. Jacobsen, L. K., Staley, J. K., Zoghbi, S. S., Seibyl, J. P., Kosten, T. R., Innis, R. B., and Gelernter, J., Prediction of dopamine transporter binding availability by genotype: A preliminary report. Am J Psychiatry 157:(10)1700-1703 (2000).
204. Van Dyck, C. H., Malison, R. T., Jacobsen, L. K., Seibyl, J. P., Staley, J. K., Laruelle, M., Baldwin, R. M., Innis, R. B., and Gelernter, J., Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med. 46:(5)745-751 (2005).
205. Jonsson, E. G., Nothen, M. M., Gustavsson, J. P., Neidt, H., Bunzel, R., Propping, P., and Sedvall, G. C., Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res. 79:(1)1-9 (1998).
206. Laruelle, M., Abi-Dargham, A., VanDyck, C. H., Rosenblatt, W., Zea-Ponce, Y., Zonghbi, S. S., Baldwin, R. M., Charney, D. S., Hoffer, P. B., and Kung, H. F. E. A., SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 36:(7)1182-1190 (1995).
207. Miller, M. A. and Hughes, A. L., Epidemiology of amphetamine use in teh United States., in Amphetamine and its Analogs. (A. K. Cho, and D. S. Segal, Eds.), Academic Press, San Diego, 1994, pp. 503.
208. Robbins, T. W., Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res. 133:(1)130-8 (2000).
209. Kimberg, D.Y.,D'Esposito,M., and Farah,M. J., Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport. 8:(16)1-5 (1997).
210. Mehta, M. A., Owen, A. M., Sahakian, B. J., Mavaddat, N., Pickard, J. D., and Robbins, T.W., Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci. 20:(6)RC65 (2000).
211. Mitchell, S. H., Laurent, C. L., and de Wit, H., Interaction of expectancy and the pharmacological effects of d-amphetamine: Subjective effects and self-administration. Psychopharmacology 125:(4)371-378 (1996).
212. Cesarec, Z. and Nyman, A. K., Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand. 71:(5)523-538 (1985).
213. Hutchison, K. E., Wood, M. D., and Swift, R., Personality factors moderate subjective and psychophysiological responses to d-amphetamine in humans. Exp Clin Psychopharmacol. 7:(4)493-501 (1999).
214. White, T. L., Justice, A. J., and de Wit, H., Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav. 73:(4)729-741 (2002).
215. Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., and Weinberger, D. R., Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 100:(10)6186-6191 (2003).
216. Dlugos, A., Freitag, C., Hohoff, C.,McDonald, J. S., Cook, E. H., Deckert, J., and de Wit, H., Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry. 61:(11)1296-1305 (2007).
217. Lott, D. C., Kim, S. J., Cook, E. H., and de Wit, H., Serotonin transporter genotype and acute subjective response to amphetamine. Am J Addict. 15:(5)327-335 (2006).
218. Hohoff, C., McDonald, J. M., Baune, B. T., Cook, E. H., Deckert, J., and de Wit, H., Interindividual variation in anxiety response to amphetamine: Possible role for adenosine A2A receptor gene variants. Am J Med Genet B Neuropsychiatr Genet. 139:(1)42-44 (2005).
219. Veenstra-VanderWeele, J., Qaadir, A., Palmer, A. A., Cook, E. H. J., and de Wit, H., Association between the casein kinase 1 epsilon gene region and subjective response to Damphetamine. Neuropsychopharmacology. 31:(5)1056-1063 (2006).
220. Flanagin, B. A., Cook, E. H. J., and de Wit, H., An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response. Am J Med Genet B Neuropsychiatr Genet. 141:(6)576-583 (2006).
221. Vandenbergh, D. J., Persico, A. M., Hawkins, A. L., Griffin, C. A., Li, X., Jabs, E. W., and Uhl, G. R., Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 14:(4)1104-1106 (1992).
222. Haertzen, C. A., Kocher, T. R., andMiyasato, K., Reinforcements from the first drug experience can predict later drug habits and/or addiction: Results with coffee, cigarettes, alcohol, barbiturates, minor and major tranquilizers, stimulants, marijuana, hallucinogens, heroin, opiates and cocaine. Drug Alcohol Depend. 11:(2)147-165 (1983).
223. Fergusson, D. M., Horwood, L. J., Lynskey, M. T., and Madden, P. A., Early reactions to cannabis predict later dependence. Arch Gen Psychiatry. 60:(10)1033-1039 (2003).
224. Gulley, J. M., Everett, C. V., and Zahniser, N. R., Inbred Lewis and Fischer 344 rat strains differ not only in novelty- and amphetamine-induced behaviors, but also in dopamine transporter activity in vivo. Brain Res. 1151:(2)32-45 (2007).
225. Haile, C. N., Zhang, X. Y., Carroll, F. I., and Kosten, T. A., Cocaine selfadministration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter. Brain Res. 1055:(1-2)186-195 (2005).
226. Lake, C. R. and Quirk, R. S., CNS stimulants and the look-alike drugs. Psychiatr Clin North Am 7:689-701 (1984).
227. Cook, C. E., Jeffcoat, A. R., Hill, J. M., Pugh, D. E., Patetta, P. K., Sadler, B. M., White, W. R., and Perez-Reyes, M., Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S- (+)-methamphetamine hydrochloride. Drug Metab Dispos. 21:717-723 (1993).
228. Fischman, M. W. and Schuster, C. R., Tolerance development to chronic methampetamine intoxication in the rhesus monkey. Pharmacol Biochem Behav. 2:503-508 (1974).
229. Perez-Reyes, M., White, W. R., McDonald, S. A., Hicks, R. E., Jeffcoat, A. R., Hill, J. M., and Cook, C. E., Clinical effects of daily methamphetamine administration. Clin Neuropharmacol. 14:352-358 (1991).
230. Martin,W. R., Sloan, J.W., Sapira, J. D., and Jasinski, D. R., Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 12:245-248 (1971).
231. Gawin, F. H. and Ellinwood, E. H. J., Cocaine and other stimulants. Actions, abuse, and treatment. N Engl J Med. 318:1173-1182 (1988).
232. Cretzmeyer, M., Sarrazin, M. V., Huber, D. L., Block, R. I., and Hall, J. A., Treatment ofmethamphetamine abuse: Research findings and clinical directions. J Subst Abuse Treat. 24:267-277 (2003).
233. Newton, T. F., Kalechstein, A. D., Duran, S., Vansluis, N., and Ling, W., Methamphetamine abstinence syndrome: Preliminary findings. Am J Addict. 13:248-255 (2004).
234. Srisurapanont, M., Ali, R., Marsden, J., Sunga, A., Wada, K., and Monteiro, M., Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 6:347-352 (2003).
235. Yui, K., Ikemoto, S., Ishiguro, T., and Goto, K., Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci. 914:1-12 (2000).
236. Akiyama, K., Kanzaki, A., Tsuchida, K., and Ujike, H., Methamphetamine-induced behavioral sensitization and its implications for relapse of schizophrenia. Schizophrenia Res. 12:251-257 (1994).
237. Rose, M. E. and Grant, J. E., Pharmacotherapy for methamaphetamine dependence: A review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry 20:(3)145-155 (2008).
238. Zetterstrom, T., Sharp, T., Collin, A. K., and Ungerstedt, U., In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur J Pharmacol 148:327-334 (1988).
239. Fischer, J. and Cho, A., Chemical release of dopamine from striatal homogenates: Evidence for an exchange diffusion model. J Pharmacol Exp Ther. 208:203-209 (1979).
240. Cubells, J. F., Rayport, S., Rajendran, G., and Sulzer, D., Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci. 14:(4)2260-2271 (1994).
241. Liu, Y. and Edwards, R. H., The role of vesicular transport porteins in synaptic transmission and neural degeneration. Annu Rev Neurosci. 20:125-156 (1997).
242. Berman, S. B., Zigmond, M. J., and Hastings, T. G., Modification of dopamine transporter function: Effect of reactive oxygen species and dopamine. J Neurochem. 67:593-600 (1996).
243. Fleckenstein, A. E., Metzger, R. R., Beyeler, M. L., Gibb, J. W., and Hanson, G. R., Oxygen radicals diminish dopamine transporter function in rat striatum. Eur J Pharmacol. 334:111-114 (1997).
244. Kokoshka, J. M., Vaughan, R. A., Hanson, G. R., and Fleckenstein, A. E., Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol. 361:269-275 (1998).
245. Davidson, C., Gow, A. J., Lee, T. H., and Ellinwood, E. H., Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev. 36:1-22 (2001).
246. Cho, A. K. and Melega, W. P., Patterns of methamphetamine abuse and their consequences. J Addict Dis. 21:21-34 (2002).
247. Kita, T., Wagner, G. C., and Nakashima, T., Current research on methamphetamine-induced neurotoxicity: Animal models of monoamine disruption. J Pharmacol Sci. 92:178-195 (2003).
248. Metzger, R. R., Haughey, H. M., Wilkins, D. G., Gibb, J. W., Hanson, G. R., and Fleckenstein, A. E., Methamphetamine-induced rapid decrease in dopamine transporter function: Role of dopamine and hyperthermia. J Pharmacol Exp Ther. 295:1077-1085 (2000).
249. Ujike, H., Onoue, T., Akiyama, K., Hamamura, T., and Otsuki, S., Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 98:89-92 (1989).
250. Witkin, J.M., Savtchenko, N., Mashkovsky,M., Beekman, M.,Munzar, P., Gasior, M., Goldberg, S. R., Ungard, J. T., Kim, J., Shippenberg, T., and Chefer, V., Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: Comparisons with methamphetamine. J Pharmacol Exp Ther. 288:1298-1310 (1999).
251. Wong, A. H. C. and VanTol, H. H. M., The dopamine D4 receptors and mechanisms of antipsychotic atypicality . Prog Neuropsychopharmacol Biol Psychiatry. 27:1091-1099 (2003).
252. Okuyama, S., Kawashima, N., Chaki, S., Yoshikawa, R., Funakoshi, T., Ogawa, S. I., Suzuki, Y., Ideda, Y., Kumagai, T., Nakazato, A., Nagamine, M., and Tomisawa, K., A selective dopamine D4 receptor antagonist, NRA0160: A preclinical neuropharmacological profile. Life Sci. 65:2109-2125 (1999).
253. Kamei, H., Nagai, T., Nakano, H., Togan, Y., Takayanagi, M., Takahashi, K.,Kobayashi, K.,Yoshida, S., Maeda, K., Takuma, K., Nabeshima, T., and Yamada, K., Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 59:(1)75-84 (2006).
254. Wachtel, S. R.,Ortengren, A., and De Wit, H., The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend. 68:(1)23-33 (2002).
255. McCann, U. D.,Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., and Ricaurte, G. A., Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 18:8417-8422 (1998).
256. Sekine, Y., Iyo, M., Ouchi, Y., Matsunaga, T., Tsukada, H., Okada, H., Yoshikawa, E., Futatsubashi, M., Takei, N., and Mori, N., Methamphetamine- related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 58:1206-1214 (2001).
257. Iyo, M., Sekine, Y., and Mori, N., Neuromechanism of developing methamphetamine psychosis: A neuroimaging study. Ann N Y Acad Sci. 1025:288-295 (2004).
258. Chen, C. K., Hu, X., Lin, S. K., Sham, P. C., el-W, L., Li, T.,Murray, R. M., and Ball, D. M., Association analysis of dopamine D2-like receptor genes and methamphetamine abuse. Psychiatr Genet. 14:(4)223-226 (2004). (Pubitemid 40054350)
259. Liu, H. C., Lin, S. K., Liu, S. K., Chen, S. L., Hu, C. J., Chang, J. G., and Leu, S. J., DAT polymorphism and diverse clinical manifestations in methamphetamine abusers. Psychiatr Genet. 14:(1)33-37 (2004).
260. Vandenbergh, D. J., Rodriguez, L. A., Hivert, E., Schiller, J. H., Villareal, G., Pugh, E.W., Lachman, H., and Uhl, G. R., Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: No interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene. Am J Med Genet. 96:(5)678-683 (2000).
261. Hośak, L., Libiger, J., Cizek, J., Beŕanek, M., and Cerḿakov́a, E., The COMT Val158Met polymorphism is associated with novelty seeking in Czech methamphetamine abusers: Preliminary results. Neuro Endocrinol Lett. 27:(6)799-802 (2006).
262. Suzuki, A., Nakamura, K., Sekine, Y., Minabe, Y., Takei, N., Suzuki, K., Iwata, Y., Kawai, M., Takebayashi, K., Matsuzaki, H., Iyo, M., Ozaki, N., Inada, T., Iwata, N., Harano, M., Komiyama, T., Yamada, M., Sora, I., Ujike, H., andMori, N., An association study between catechol-O-methyl transferase gene polymorphism andmethamphetamine psychotic disorder. Psychiatr Genet. 16:(4)133-138 (2006).
263. Ujike, H., Harano, M., Inada, T., Yamada, M., Komiyama, T., Sekine, Y., Sora, I., Iyo, M., Katsu, T., Nomura, A., Nakata, K., and Ozaki, N., Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenetics J. 3:(4)242-247 (2003).
264. Matsuzawa, D., Hashimoto, K., Miyatake, R., Shirayama, Y., Shimizu, E., Maeda, K., Suzuki,Y., Mashimo,Y., Sekine,Y., Inada, T., Ozaki, N., Iwata, N., Harano, M., Komiyama, T., Yamada, M., Sora, I., Ujike, H., Hata, A., Sawa, A., and Iyo, M., Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry. 164:(7)1105-1114 (2007).
265. Zimniak, P., Nanduri, B., Pikua, S., Bandorowicz-Pikua, J., Singhal, S. S., Srivastava, S. K., Awasthi, S., and Awasthi, Y. C., Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 224:(3)893-899 (1994).
266. Hashimoto, T., Hashimoto, K., Matsuzawa, D., Shimizu, E., Sekine, Y., Inada, T., Ozaki, N., Iwata, N., Harano, M., Komiyama, T., Yamada, M., Sora, I., Ujike, H., and Iyo, M., A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am J Med Genet B Neuropsychiatr Genet. 135:(1)5-9 (2005).
267. Aoyama, N., Takahashi, N., Kitaichi, K., Ishihara, R., Saito, S., Maeno, N., Ji, X., Takagi, K., Sekine,Y., Iyo, M.,Harano, M.,Komiyama, T.,Yamada, M., Sora, I., Ujike, H., Iwata, N., Inada, T., and Ozaki, N., Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res. 30:(10)1644-1649 (2006). (Pubitemid 44465604)
268. Ikeda, M., Ozaki, N., Suzuki, T., Kitajima, T., Yamanouchi, Y., Kinoshita, Y., Kishi, T., Sekine, Y., Iyo, M., Harano, M., Komiyama, T., Yamada, M., Sora, I., Ujike, H., Inada, T., and Iwata, N., Possible association of betaarrestin 2 genewith methamphetamine use disorder, but not schizophrenia. Genes Brain Behav. 6:(1)107-112 (2007).
269. Ide, S., Kobayashi, H., Tanaka, K., Ujike, H., Sekine, Y., Ozaki, N., Inada, T., Harano, M., Komiyama, T., Yamada, M., Iyo, M., Ikeda, K., and Sora, I., Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci. 1025:(Oct)316-324 (2004).
270. Ide, S., Kobayashi, H., Ujike, H., Ozaki, N., Sekine, Y., Inada, T., Harano, M., Komiyama, T., Yamada, M., Iyo, M., Iwata, N., Tanaka, K., Shen, H., Iwahashi, K., Itokawa, M., Minami, M., Satoh, M., Ikeda, K., and Sora, I., Linkage disequilibrium and association with methamphetamine dependence/psychosis of muopioid receptor gene polymorphisms. Pharmacogenomics J. 6:(3)179-188 (2006). (Pubitemid 43811569)
271. Kobayashi, H., Hata, H., Ujike, H., Harano, M., Inada, T., Komiyama, T., Yamada,M., Sekine, Y., Iwata, N., Iyo, M., Ozaki, N., Itokawa,M., Naka, M., Ide, S., Ikeda, K., Numachi, Y., and Sora, I., Association analysis of delta-opioid receptor gene polymorphisms in methamphetamine dependence/ psychosis. Am J Med Genet B Neuropsychiatr Genet. 141:(5)482-486 (2006). (Pubitemid 44024442)
272. Poo, M. M., Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2:(1)24-32 (2001).
273. Tyler, W. J., Alonso, M., Bramham, C. R., and Pozzo-Miller, L. D., From acquisition to consolidation: On the role of brain-derived neurotrophic factor signaling in hippocampal-dependent learning. Learn Mem. 9:(5)224-237 (2002).
274. Horger, B. A., Iyasere, C. A., Berhow, M. T., Messer, C. J., Nestler, E. J., and Taylor, J. R., Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci. 19:(10)4110-4122 (1999).
275. Bolaños, C. A. and Nestler, E. J., Neurotrophic mechanisms in drug addiction. Neuromolecular Med. 5:(1)69-83 (2004).
276. Jockers-Scherübl, M. C., Danker-Hopfe, H., Mahlberg, R., Selig, F., Rentzsch, J., Schürer, F., Lang, U. E., and Hellweg, R., Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse andmultiple substance abuse. Neurosci Lett. 371:(1)79-83 (2004).
277. Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., Lu, B., and Weinberger, D. R., The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 112:(2)257-269 (2003).
278. Cheng, C. Y., Hong, C. J., Yu, Y. W., Chen, T. J., Wu, H. C., and Tsai, S. J., Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res. 140:(1-2)86-90 (2005).
279. Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., and Weinberger, D. R., Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. 23:(17)6690-6694 (2003).
280. Liu, Q. R., Walther, D., Drgon, T., Polesskaya, O., Lesnick, T. G., Strain, K. J., De Andrade, M., Bower, J. H., Maraganore, D. M., and Uhl, G. R., Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am JMed Genet B Neuropsychiatr Genet. 134:(1)93-103 (2005).